Retrophin to Present at the Jefferies 2020 Virtual Healthcare Conference
Retrophin, a biopharmaceutical firm, announced that its CEO, Eric Dube, Ph.D., will present at the Jefferies 2020 Virtual Healthcare Conference on June 3, 2020, at 2:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Retrophin, a biopharmaceutical firm, announced that its CEO, Eric Dube, Ph.D., will present at the Jefferies 2020 Virtual Healthcare Conference on June 3, 2020, at 2:30 p.m. ET. A live webcast will be available, with an archived replay accessible for 30 days.
The company focuses on developing therapies for rare diseases, particularly sparsentan for FSGS and IgAN. Retrophin is also conducting research on other rare conditions like NGLY1 deficiency and Alagille syndrome, supported by revenues from its commercial products such as Chenodal®, Cholbam®, and Thiola®.
Details
News Market Reaction – RTRX
The recorded move for RTRX in the trading session of this news was -0.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the Jefferies 2020 Virtual Healthcare Conference on Wednesday, June 3, 2020 at 2:30 p.m. ET.
A live webcast of the presentation will be available at http://ir.retrophin.com/events and an archived replay will be accessible for up to 30 days.
About Retrophin
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including partnerships with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam®, Thiola® and Thiola EC®.
Retrophin.com
Contact:
Chris Cline, CFA
Senior Vice President, Investor Relations & Corporate Communications
888-969-7879
IR@retrophin.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.